Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
Satoshi IkedaTerufumi KatoTakashi OguraAkimasa SekineTsuneyuki OdaNoriyuki MasudaSatoshi IgawaKen KatonoSakiko OtaniKouzo YamadaHaruhiro SaitoTetsuro KondoYukio HosomiYoshiro NakaharaMasanori NishikawaKeiko UtumiYuki MisumiTakeharu YamanakaKentaro SakamakiHiroaki OkamotoPublished in: BMC cancer (2018)
UMIN Clinical Trial Registry; UMIN000004368 . Registered date; October 11, 2010 (Retrospectively registered).
Keyphrases
- phase ii study
- open label
- locally advanced
- clinical trial
- endothelial cells
- metastatic colorectal cancer
- phase ii
- rectal cancer
- palliative care
- spinal cord
- high grade
- squamous cell carcinoma
- radiation therapy
- phase iii
- study protocol
- placebo controlled
- low grade
- double blind
- high glucose
- randomized controlled trial
- vascular endothelial growth factor
- spinal cord injury